Michael Bowen

Company: Kinoxis Therapeutics

Job title: Chief Scientific Officer

Seminars:

Combining Animal Models with Advanced Neuroscience, Machine Learning, and Drug Delivery Technologies to Advance KNX100 for the Treatment of Agitation in Dementia & Substance Use Disorders 12:15 pm

KNX100 is a novel, clinical-stage treatment being developed for the treatment of agitation in dementia and substance use disorders Using time-locked, high temporal resolution neural and video recordings to enhance confidence in the disease relevance of preclinical behavioural and biological readouts Chronic steady-state dosing in animal models to improve the precision and predictive utility of…Read more

day: Day One Track A AM

Enhancing the Selectivity, Sensitivity & Predictive Validity of Animal Models to Successfully Translate Novel Antidepressant, Antipsychotic & Anxiolytic Therapeutics 1:01 pm

With a pressing need for in vivo assays that more accurately predict the effects of antidepressants, antipsychotics and anxiolytics in humans, join this collaborative workshop to benchmark new strategies, from recreating exact phenotypes to optimizing dose selection, to bridge the translational gap. Highlights Include: Leveraging advancements in systems neuroscience: which animal behaviours are meaningful indicators…Read more

day: Workshop Day